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Strengths and limitations of this study
 ► First audit of the Integrated Research Application 
System (IRAS) to investigate trial investigators 
reported intention to disseminate trial results to 
participants.
 ► Describes frequency of intention to disseminate and 
reported plans for dissemination.
 ► Links End of Study reports to original IRAS applica-
tions and provides a summary of overall behaviours 
about reporting of dissemination of results in said 
reports.
 ► Linkage with End of Study reports to report actual 
behaviour regarding dissemination is limited due 
to no explicit requirement from Health Research 
Authority to report this activity in final report.
AbStrACt
Objective To determine the proportion of Phase III clinical 
trials given a favourable opinion by a research ethics 
committee in the UK that provided trial results to those 
who participated.
Design Audit of records.
Setting Phase III clinical trials registered on the UK’s 
research permissions system (Integrated Research 
Application System) between the 1 January 2012 to 31 
December 2017.
Main outcome measures Proportion of trial investigators 
that intended to provide results to trial participants 
compared against what trials reported to ethics 
committees at the end of study.
results Out of 1404 Phase III trials, 87.7% (n=1231) 
trials stated they intended to disseminate results to 
participants while 12.3% (n=173) trials stated they 
would not. Out of these 1231 trials, 18.8% (n=231) trials 
intended to actively communicate trial results or a means 
of accessing results to their participants, a further 80.5% 
(n=991) reported passive intention to disseminate and for 
the remainder (n=9) the process was unclear. Of the 370 
End of Study reports (30% of all included studies) that 
could be accessed 10 (2.7%) explicitly mentioned activities 
related to dissemination of findings to participants with the 
majority (74.9%) having no mention and a further 22.4% 
of reports not being accessible. Of the 10 which did report 
dissemination of results to participants the majority (n=6) 
were through a lay summary or letter.
Conclusions Reported intention to disseminate results to 
trial participants among trial investigators is high, however, 
reporting of feedback methods is lacking. In addition, 
mechanisms to ensure intentions to disseminate trial 
results are translated into actual behaviour need to be put 
in place to ensure those who participate in trials have the 
opportunity to find out about the results.
IntrODuCtIOn
Clinical trials and research are increasing 
in the UK. In 2018, a total of 870 250 partic-
ipants took part in National Institute for 
Health Research Clinical Research Network 
supported clinical research studies in 
England alone — marking an increase of 
over 140 000 over the previous year.1 The 
cumulative cost of these studies was around 
£6 billion and is likely to increase as the 
National Health Service long- term plan 
targets to include one million people taking 
part in research by 2023/2024.1 This increase 
in participants numbers has the potential 
to translate into significant improvement in 
delivery of healthcare as long as findings are 
disseminated to those with responsibility to 
make a change (policymakers) and the end 
users of the services (patients and healthcare 
professionals).
In 2008, a key review based on 28 empirical 
studies demonstrated that 90% of participants 
would want to be informed of the results of the 
research that they were involved in.2 Despite 
this interest shown by participants, little is 
being done to provide them with results.3 A 
survey on research participant experience 
showed that 90% of respondents were happy 
with the information that they received 
before or during the research. However, 
there was little indication that they were 
provided with or made aware of the opportu-
nity to access results after completion.4 This 
lack of attention to meeting expectations 
of research participants is not acceptable. 
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box 1 requested filter questions from IrAS form
A14-1. In which aspects of the research process have you actively in-
volved, or will involve, patients, service users, and/or their carers, or 
members of the public? Give details of involvement, or if none please 
justify the absence of involvement.
 ► Data provided: nominal data and open- ended text
A51. How do you intend to report and disseminate the results of the 
study?
 ► Data provided: nominal data and open- ended text
A53. Will you inform participants of the results? Please give details of 
how you will inform participants or justify if not doing so.
 ► Data provided: dichotomous data (yes/no) and open- ended text
When aligned with recent initiatives to improve research 
integrity through ensuring trials are registered and that 
their results are published, it seems an obvious next step 
to make sure those who participated in them (and who 
which without they would not be possible) are informed 
of the results.
In order to encourage the dissemination of results, 
the Health Research Authority (HRA, whose core 
purpose is ‘to protect and promote the interests of 
patients and public in health and social care research’ 
in the UK) published guidelines, recommending that all 
researchers communicate results to their study partici-
pants and at the very least offer the results.5 The guide-
lines also recommend patient and public involvement 
(PPI) in all aspects of the research process.5 This refers 
to the involvement of patients and/or members of the 
public in the design or undertaking of the research 
process.6 An example of this would be patient input 
regarding the mode of dissemination of results in order 
to improve the feedback process. These contributions 
can be very valuable as they can provide an alternative 
perspective that the researchers may not have consid-
ered and can ensure the materials are accessible to non- 
experts. Unlike the dissemination of results, which is not 
mandatory for Phase III trials, the inclusion of PPI in 
the research process is mandated by funding bodies as a 
prerequisite to obtaining funding.
In the UK, applications for ethical approval are made 
through the Integrated Research Application System 
(IRAS). The IRAS form includes questions regarding the 
researchers' intention to disseminate results to partici-
pants as well as any intended PPI. On completion, the 
research team must then submit a declaration of end of 
study to the research ethics committee (REC) followed 
by a final ethics report within 12 months of the comple-
tion of the study (the End of Study report). The final 
ethics report should confirm any steps taken to dissemi-
nate results to participants.7 The guidelines also instruct 
researchers about the information to be included in the 
patient’s end of study information sheet, which should as 
a minimum offer the results and specify when and how 
participants should expect to receive results.
In addition, this national level guidance, there is inter-
national recognition of the ethical imperative (specified 
within the Declaration of Helsinki) to offer results which 
is represented by the statement ‘all medical research 
subjects should be given the option of being informed 
about the general outcome and results of the study’.8
While there is a need to provide results of any research 
study which a participant has contributed to, providing 
results from clinical trials has salience in the current 
research transparency landscape.9 Phase III clinical trials 
also hold a position of particular importance given all 
participants will have had no choice in the treatment 
they received, many may not know what intervention they 
received, several will have provided data through patient 
reported outcomes and many are publicly funded. At the 
very least, trial teams should be making the results of the 
studies to which these individuals contribute to available 
and accessible to them in appropriate ways.
This study aims to assess whether researchers in the UK 
intend to inform participants of the trial results, plans 
for how results are provided, how patients are involved 
in this process and finally, whether those trial teams that 
intended to provide results report this activity in their 
End of Study reports.
MethODS
Inclusion criteria
This study included all applications on the IRAS during 
the period 1 January 2012 to 31 December 2017 where 
the research team had selected filter question (defining 
the work as a clinical trial) and that had received a favour-
able REC opinion and carried out in the UK. IRAS is the 
UK’s online system for the permissions and approvals for 
health, social and community care research.
Data request and extraction
Information regarding the IRAS form submitted by 
researchers was requested from the HRA. Specific data 
on study descriptors such as: IRAS Project ID; REC name; 
REC reference; Study title; Protocol version and date; 
etc, was requested. In addition, data from project rele-
vant questions, relating to patient and public involve-
ment, plans for dissemination and whether participants 
would receive results, from within the IRAS form were 
requested, (see Box 1 for the specific questions and the 
data types contained within them). On receipt of the 
data from IRAS, additional criteria were applied to select 
Phase III clinical trials for inclusion (filtering to select 
only those studies that reported ‘Yes’ to the filter ‘Ther-
apeutic confirmatory trial (Phase III)’. The rationale for 
only including Phase III randomised controlled trials in 
this audit was due to Phase III trials largely collecting 
patient- reported outcomes, for which there may be more 
potential for demonstrable change in practice and as such 
greater buy in from participants to receive the overall 
results from the data collected.
The data items requested from IRAS were specified in 
the ‘HARP Software Change/Management Information 
Request Form’. In addition to the data contained within 
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Figure 1 Summary of search results.
IRAS we also requested access to final ethics reports 
(ie, the End of Study reports) through the HRA Assess-
ment Review Portal (HARP) in order to confirm a match 
between information provided in the IRAS form about 
what was planned for feeding back results to participants 
with what actually happened, as reported in the final 
report. Final reports were identified by searching for 
specific REC reference identification numbers within 
HARP.
Data analysis
IRAS responses which provided nominal data were 
summarised using descriptive statistics such as frequen-
cies and percentages for example, ‘Will you inform partic-
ipants of the results? – Yes/No?’. Free text responses were 
categorised using content analysis. Single level coding 
was applied, codes were developed iteratively in discus-
sion between team members and coding was performed 
by one team member. In order to assess the involvement 
of trial teams in the act of dissemination, our team cate-
gorised the intended means of dissemination of results as 
being either active or passive:
 ► Active: The trial team directly informed participants 
of the means by which the results could be accessed. 
For example, by a letter or by including a web link to 
the results.
 ► Passive: Trial team did not directly inform participants 
of a means to access trial results. For example, where 
the responsibility to forward the results was placed on 
the site team.
Patient and public involvement
This audit forms part of a larger project that aims to 
develop recommendations for researchers on how to 
report clinical trial results appropriately to participants 
(RECAP: researchregistry4085). There are two patient 
partners on the Advisory group for the RECAP project 
who have contributed to this substudy through discussion 
of results at team meetings. In addition, the HRA patient 
and public involvement lead has also been involved 
in conversations about this audit and had opportunity 
to comment and guide interpretation of the results in 
advance of final analysis.
reSultS
Data mining
Data on a total of 6826 trials (which had received a favour-
able opinion from a REC) was received in the initial data 
set collated by the HRA based on the requested filter 
questions. One thousand four hundred and four of these 
were identified as Phase III trials as prespecified by the 
trial team on the IRAS system (studies that reported ‘Yes’ 
to the filter ‘Therapeutic confirmatory trial (Phase III) 
– figure 1).
Intention to disseminate
A total of 1231 (87.7%) trial teams stated they intended 
to disseminate results to participants while 173 (12.3%) 
trials stated they would not. Researchers were then asked 
to provide details on how they intended to do so. Of those 
that said yes, we identified 231 (18.8%) as reporting an 
active effort to disseminate results, that is, the trial team/
sponsor actively made arrangements to provide partici-
pants with results. The most commonly reported mode 
of active dissemination was directing participants to a 
website with results (see table 1). This was reported in 
74 (32%) of trials that planned to actively disseminate to 
participants. Some trials included this at the beginning of 
the trial in the Participant Information Leaflet or at the 
end of participants involvement in the End of Study infor-
mation sheet. Fifty- three (22.9%) trial teams stated that 
they intended to provide either lay summaries or infor-
mation sheets but did not specify any other information. 
Forty- four (19%) intended to send the results by mail 
directly to the participants. The ‘other’ category involves 
4 (1.7%) trials that included reasons such as organising 
‘dissemination events’ and holding meetings with the 
participants.
Within the trials whose teams reported an intention 
to disseminate results to participants, we coded 991 as 
reporting a passive method to disseminate results that 
is, there were no formal arrangements made to provide 
patients with access to the results. The most common 
method of passive dissemination stated the local site 
team, such as the study doctors or trial investigators, 
would provide results at their discretion. This accounted 
for 549 (55.4%) trials. Another 339 (34.2%) trial teams 
stated that results would be provided on request but did 
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Table 1 Summary of trial team responses regarding intention to disseminate
Means of dissemination
Intention to disseminate results to participants
Yes No
Active
Provision of web link to results 74 (32%) –
Postal letter 44 (19%) –
Patient information sheet 37 (16%) –
Clinic appointment 23 (10%) –
Lay patient summary 16 (6.9%) –
Patient choice of mode of delivery 16 (6.9%) –
PPI group 10 (4.3%) –
Newsletter 5 (2.2%) –
Email 2 (0.9%) –
Other (eg, face- to- face meetings) 4 (1.7%) –
Total 231 (18.8%) -
Passive
Trial linked staff (eg, discretion of study doctor) 549 (55.4%) 72 (41.6%)
Participant initiated request 339 (34.2%) 49 (28.3%)
Public domain (trial website) 84 (8.5%) 24 (13.9%)
Conference/scientific publication 17 (1.7%) –
Media 1 (0.1%) –
Public representative meeting 1 (0.1%) –
No reason stated – 24 (13.9%)
Other – 4 (2.3%)
Total 991 (80.5%) 173 (100%)
Unclear 9 (0.7%) -
TOTAL 1231 173
PPI, patient and public involvement.
not specify how the participants would be given the oppor-
tunity to request results. Finally, 84 (8.5%) intended to 
make the results available in the public domain but did 
not specify how the participants would be informed of or 
directed to these results.
Responses coded as ‘Unclear’ (of which there were 9, 
0.7%) either left the question unanswered or provided 
a vague statement. For example, ‘Participants will be 
informed of the results post- study.’
A total of 173 (12.3%) trial teams reported that they 
did not intend to provide participants with the results. 
Of these, 72 (41.6%) stated that there were no plans to 
disseminate results, but that study investigators or study 
doctors may pass on the results. Forty- nine (28.3%) 
stated that results would be provided if the participants 
expressed an interest or requested them. Twenty- four 
(13.9%) provided no reason. Another 24 (13.9%) stated 
that results would be made available in the public domain 
but not sent to participants directly. ‘Other’ (n=4, 2.3%) 
includes trials that mentioned the use of patient groups 
to disseminate results or provided non- specific statements 
such as ‘Patients will be informed about the results of 
their study in an individual manner’.
Patient and public involvement
We also wanted to determine whether those trials that 
planned to disseminate results to trial participants were 
better overall at including patients in the design and 
conduct of the trial. Therefore, we analysed whether and 
how the trial teams that intended to disseminate results 
included patients as partners in their studies.
Within the sample of 1231 who planned to dissem-
inate results to participants, 381 (31%) trial teams also 
reported they intended to involve patients or the public 
in the design or conduct of their trial. The largest propor-
tion of PPI was observed in the dissemination phase with 
227 trials accounting for 59.6% while only 4.5% (n=17) 
of trial teams proposed input during the analysis phase. 
Elsewhere, 180 (47.2%) reported they would incorporate 
PPI in the design phase of the research; 123 (32.3%) 
would seek input while the undertaking of the trial and 
121 (31.7%) proposed to involve patients or public in the 
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Table 2 Researcher- reported patient and public involvement in trial design and/or conduct
Aspect of trial
IRAS- reported PPI in design and/or conduct of trial
Intention to disseminate results to participants 
(n=381)
No intention to disseminate results to participants 
(n=42)
Frequency % Frequency %
Design 180 47.2 16 38.1
Management 121 31.7 6 14.3
Undertaking 123 32.3 28 66.7
Analysis 17 4.5 2 4.8
Dissemination 227 59.6 11 26.2
*Totals for % are greater than 100 as categories are not mutually exclusive and research teams could report PPI across several aspects of the 
research.
IRAS, Integrated Research Application System; PPI, patient and public involvement.





Sufficient expertise 244 28.7
Sponsor responsibility 145 17.1




Inappropriate – complexity of trial 83 9.8
Commercial trial 82 9.6




Prescribed research design 12 1.4
Other 34 3.9
TOTALS 850 100
management phase (see table 2). It is important to note 
that involvement was not mutually exclusive to one indi-
vidual design or conduct category and researchers could 
select involvement across multiple categories.
Forty- two (24%) of the 173 trial teams that had no 
intention of disseminating results back to participants did 
report patient or public involvement in at least one aspect 
of the trial process. Within this sample of 42, undertaking 
the research was reported most frequently as involving PPI 
(n=28, 66.6%), followed by design (n=16, 38.1%), dissem-
ination (n=11, 26.2%), management (n=6, 14.3%) and 
analysis (n=2, 4.8%). Again, it is important to note that 
involvement was not mutually exclusive to one category.
A total of 850 (69%), from the 1231 trial teams that 
intended to disseminate result to participants, stated they 
would not be involving PPI partners at any stage of the 
research process. Among these, 244 (28.7%) deemed PPI 
to be unnecessary due to the sufficient expertise present 
among the members of the research team or other sources 
for example, ‘It was felt that sufficient input had been 
gained from other sources’. A further 213 (25.1%) trials 
responded that it was inappropriate to involve members 
of the public due to the complex or experimental nature 
of the trial or the use of an unlicensed drug. One hundred 
and forty- five (17.1%) trials stated that all aspects of the 
research process were sole responsibility of the trial 
sponsor. One hundred and five (12.4%) trials did not 
provide an explanation for not doing so. ‘Other’ involved 
34 (3.9%) trials that do not give a specific reason for the 
lack of PPI or simply describe the details of the trial itself. 
For example, ‘no patients, services and/or their carers or 
members of the public were involved with the design of 
the protocol’. Finally, ‘Prescribed design’ accounted for 
12 (1.4%) of the responses, which refers to studies that 
are using previously implemented trial designs and who 
deemed PPI not necessary. Responses are summarised in 
table 3.
end of study report
Data for the 1231 trial teams that intended to dissemi-
nate results was extracted from HARP to identify, first, 
whether these studies submitted an End of Study report. 
A large proportion of trials (n=517 (42%)) were still 
in progress when the data was requested while 90 trials 
(7.3%) had been terminated or abandoned and as such 
no End of Study reports were available for these trials. Of 
the 624 completed trials, 370 (59.3% of completed trials 
and 30.1% total sample) submitted a final ethics report, 
while 127 (20.4% of completed trials and 10.3% of total 
sample) failed to do so and 127 (20.4% of completed 
trials and 10.3% of total sample) had incomplete data 
registered within the HARP system making analysis diffi-
cult. (table 4).
Of the 370 studies that did submit an End of Study 
report, the majority of the trial teams (n=277, 74.9%) 
did not mention any arrangements made regarding the 
dissemination of trial results back to participants yet all 
expressed intention to do so on the original IRAS appli-
cation. Six studies (1.6%) provided a copy of the lay 
summary or referred to it in the report or the cover letter. 
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Table 4 End of study report status
Report status Frequency (n)
% of 
total
Completed trials Submitted 370 30.0




Trial in progress† 517 42.0
Trial terminated/abandoned 90 7.3
TOTAL 1231 100
*Incomplete HARP data: HARP has trial registered but is 
incomplete. For example, does not clearly state that trial ever 
started/little or no documentation uploaded to HARP.
†Trial in progress: trial currently recruiting or in follow- up, or, not 
yet started, or, trial complete and not reported but has up to 12 
months to report.
HARP, HRA Assessment Review Portal; HRA, Health Research 
Authority.
Table 5 Reporting of dissemination of result to trial participants in end of study reports
Dissemination of results reported 2013 2014 2015 2016 2017 2018 2019
TOTAL
(n/%)
No mention * 23 42 58 65 53 35 277 (74.9)
Confirmation of lay summary/letter* – – – – 1 3 2 6 (1.6)
Patient end of study sheet attached – – – – – 1 1 2 (0.5)
Follow- up visit – – – – – – 1 1 (0.3)
Presentation at scientific conference – – * – – – – 1 (0.3)
Report inaccessible† 5 3 7 3 16 32 17 83 (22.4)
TOTAL 6 26 50 61 82 89 56 370 (100)
*Confirmation of lay summary/letter either as an attached copy or mentioned in final report/cover letter.
†Report inaccessible: Reports that require password/email access or have to be uploaded by the REC.
REC, research ethics committee.
Evidence of other strategies used to inform participants 
of the trial results were also poorly represented with 2 
(0.5%) studies providing the patient End of Study sheet, 
1 (0.3%) offering a final follow- up visit, and another 1 
(0.3%) mentioning presentation at a scientific confer-
ence. While indicating the End of Study reports had been 
uploaded, the reports of 83 (22.4%) trials were inacces-
sible due to some requiring passwords or email access or 
yet to be uploaded by the REC to the HARP system. There-
fore, details from these reports could not be extracted or 
included in the analysis, see table 5.
DISCuSSIOn
Key findings
This study reports the first audit of researcher intentions 
and self- reported behaviours with regard to dissemina-
tion of clinical trial results to participants across the UK 
using reports within the HRA regulatory system. We have 
found that while the majority (n=1231, 87.7%) of trial 
teams stated in their applications that they intended to 
disseminate trial results to the participant, less than 20% 
(n=231, 18.8%) specified some form of direct ‘active’ 
communication with their participants. The majority of 
trial teams (80.5%) left the responsibility of participants 
accessing trial results with the clinical care team or on 
the participant themselves. The other key finding relates 
to the dissemination behaviour reported by trial teams 
in their End of Study report, which demonstrated that 
59.3% of completed trials had submitted an End of Study 
report compared with 20.4% that had not. However, the 
majority (74.9%) of End of Study reports did not mention 
any arrangements for the provision of trial results to 
participants.
The findings from our study show the potential vari-
ability in reporting trial results back to participants with 
many trial teams not doing so, which is in line with find-
ings from previous studies.10 Also, the variability we iden-
tified with regard to how the results would be provided 
(ie, paper based, web- link, face- to- face meeting) have also 
been documented in the literature.2 However, variability 
of this type is much less problematic (and often warranted) 
than that for whether the results will be offered at all. It is 
important to consider that patients from different popu-
lations may require different modes of delivery that are 
appropriate for their needs. The planned changes from 
the HRA stating they will change the IRAS question from 
‘whether’ results will be disseminated to ‘when and how’ 
is welcome but research teams will still require guidance 
in the what, how and when of dissemination.5
Another interesting finding is the similarity between 
the responses provided in the trial teams applications 
that intended to provide results to participants and those 
that did not. Collectively, 72.1% of the applications where 
trial teams stated they intended to provide results relied 
on either site staff to provide results or the participants 
to request the results themselves. Interestingly, these 
two categories of responses also account for nearly 70% 
of those applications that responded with ‘No’ to inten-
tion to disseminate results. In certain cases, an identical 
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response was provided as justification for intention and 
no intention. For instance, ‘Investigators will be informed 
of the study results and may pass on the details to partic-
ipant’ was a response that was observed in both the ‘yes’ 
and ‘no’ responses and in some instances was done in 
applications submitted by the same sponsor. This raises 
a concern that the question may be interpreted differ-
ently by different researchers and that at a conceptual 
level there is a misunderstanding about what constitutes 
appropriate methods of disseminating results. Explana-
tory guidance notes within the IRAS system to ensure how 
researchers are expected to operationalise and imple-
ment the dissemination of results to trial participants may 
help to resolve some of this lack of continuity.
It is disappointing to see that 69% of the trial teams 
included in our audit had no intention to include the 
public at any stage of the research. Nearly 10% of the 
850 trials deemed it inappropriate to include the public 
due to the complexity of the trial. These findings also 
echo results from an earlier audit of patient involve-
ment in IRAS applications.11 Particular aspects or types 
of research may indeed be difficult for a lay person to 
understand; however, members of the public may still be 
able to contribute to the participant enrolment or result 
dissemination phase.12 A review of publicly funded trials 
to explore how PPI was included in grant applications 
identified that most study teams intended to have some 
form of PPI input.12 This contrasts with the findings of 
this audit and others and may reflect the requirement of 
involvement of patients and/or the public as a condition 
of funding approval. This raises the question as to whether 
there could be more linkage between funders to ensure 
that there is consistency in research teams intentions with 
regards to involvement and potentially dissemination.
Our study highlights that most End of Study reports do 
not mention dissemination of results to their participants. 
However, this may not be surprising given the current 
guidance is not directive and states, and arrangements for 
publication or dissemination of the research, including 
any feedback to participants’.13 Therefore, more explicit 
guidance from the Health Research Authority to include 
information on dissemination of result to trial partici-
pants in the End of Study report should be implemented. 
The changes planned by the HRA as part of their Trans-
parency Agenda will require sponsors to submit a lay 
summary of the trial results and will attend to aspects of 
this.5 This could be strengthened by guidance on what the 
content of the lay summary should cover and mandating 
this lay summary as a critical requirement of trial close 
out
A recent study that surveyed teams that had published 
trials (involving human participants and enrolling indi-
vidual patients) during 2014 to 2015 fund only 27% of 
their eligible sample had disseminated results back to 
participants with a further 13% planning to do so. This 
study reported a range of barriers the trial teams identi-
fied with regard to disseminating results and summarised 
these as: researchers perceptions of what interests patients 
and what they understand, challenges reaching patients, 
which patients to share with, need for early planning and 
resource, researcher motivations and situational expec-
tations, type of results to share and researcher specific 
reasons for not disseminating.10 The authors propose 
some helpful suggestions targeting multiple players 
(such as increased scrutiny from ethics review boards, 
support from journals and development of standards and 
training) with the aim of improving practice.
More directive guidance, like the planned changes 
mentioned above, from the Health Research Authority 
is required if we plan to change researcher’s behaviour 
with regard to disseminating results of trials to those who 
participated. The existing guidance published in 2015 
does not seem to have impacted on trial teams intentions 
to disseminate results . Therefore, the current approach 
of requiring research teams to submit a lay summary at 
the end of the study seems more appropriate. It would 
be helpful to go one step further and request sponsor to 
inform the HRA when and how those results have been 
offered or disseminated to participants. The participant 
dissemination activity could be triggered when the trial 
submits the End of Study report as one of the close out 
tasks for the team. In addition, the HRA may need to take 
a more proactive stance with those trial teams who do 
not submit End of Study reports. Our study has shown 
that 20.4% of the completed trials either did not submit 
reports or submitted incomplete data, which is not 
surprising given there are no consequences for failing to 
submit.
In addition to the HRA, other stakeholder in the 
research enterprise could begin to implement systems 
to ensure dissemination of results to trial participants 
becomes common place and not, at best, an afterthought. 
For example, the BMJ pledged in 2019 that they will now 
ask authors of papers to describe how and when they plan 
to disseminate findings to research participants.14
Strengths and limitations
This is the first audit of ethics applications reporting 
trial teams’ intention to disseminate results of trials to 
those who participated. Set within a 5- year time frame 
we included a large sample (n=1404) of Phase III trials, 
including a range of clinical populations, interventions, 
comparators, outcomes and supported by a range of 
funders. Other IRAS audits have been competed to assess 
registration of clinical trials given a favourable opinion by 
UK research ethics committees, which also demonstrated 
the value of audits of this type to assess current regula-
tory practice.15 However, there were limitations to our 
approach, principally that the IRAS data reports inten-
tion and not actual behaviour. There is evidence from 
health psychology that intention only explain 36% of the 
variance in behaviour and as such changing intentions 
does not necessarily engender behaviour change.16 In 
other words, the 88% of trial teams reporting they intend 
to disseminate results will likely be a much lower propor-
tion that actually do it. The other limitation to our study 
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was that we relied on the identification of phase of trial 
from trial teams. This may have introduced potential bias 
in teams misrepresenting their trials or assumptions from 
our team made with regard to these trials being true prag-
matic trials when they may have been nearer the explan-
atory end of the continuum. Linked to this, it would also 
be important to consider whether the results of our study 
are also true for other phases of trials.
COnCluSIOn
According to the HRAs IRAS system, many teams deliv-
ering Phase III trials intend to disseminate the results 
of the trial back to participants. However, reporting of 
whether this dissemination activity actually happened is 
much less clear and at best happens in less than half of 
current Phase III trials approved through IRAS. This isn’t 
surprising given trial teams are not currently mandated 
to complete End of Study reports and further still there 
are no specifications on the content of the End of Study 
reports or any associated lay summaries. There is now 
potential for this to change with the recent publication 
of the HRAs transparency agenda but researchers need 
better guidance on what to report, when and how if the 
benefits of dissemination are to be realised. Further 
research is needed to conduct more embedded method-
ological research in these areas in order to identify best 
practice about the what, how and when of disseminating 
trial result to participants.
twitter Katie Gillies @GilliesKatie
Acknowledgements We thank Bill Davidson (former joint Head of Policy for the 
Health Research Authority (HRA)) and colleagues at the HRA for enabling access 
to IRAS data, providing access to HARP and commenting on progress and initial 
results of the study (specifically, Juliet Tizzard and Jim Elliott). Thanks also to 
Graeme Maclennan for analysis advice and all members of the RECAP study team 
(Marion Campbell, Vikki Entwistle, Rosemary Humphreys, Sandra Jayacodi and 
Peter Knapp).
Contributors HB wrote the first draft of the study protocol. KG and MZR 
contributed to design of the project and development of the protocol. MZR and KG 
conducted data analysis. All authors (MZR, HB, KG) commented on the results. MZR 
wrote the first draft of the manuscript. All authors approved the final version of the 
manuscript.
Funding HB was funded by the Academy of Medical Sciences (SBF002\1014) 
and KG was funded by the Medical Research Council (MR/L01193X/1). MZR was 
unfunded and conducted this work as part of a Masters in Public Health degree.
Competing interests This audit forms part of a larger project that aims to 
develop recommendations for how to appropriately feedback trial results to those 
who participated in them. This overarching project is funded by the Academy of 
Medical Science (SBF002\1014: Chief Investigator KG and supported HB, RECAP: 
researchregistry4085). KG was supported by an MRC Methodology Research 
Fellowship (MR/L01193X/1).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data may be obtained from a third party and are not 
publicly available. Data requests should be made to the Heath Research Authority.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
OrCID iD
Katie Gillies http:// orcid. org/ 0000- 0001- 7890- 2854
reFerenCeS
 1 National Institute for health research CRN performance report 
2018/2019. Available: https://www. nihr. ac. uk/ documents/ 
performance- report- year- end- 201819/ 21871 [Accessed 07 Nov 
2019].
 2 Shalowitz DI, Miller FG. Communicating the results of clinical 
research to participants: attitudes, practices, and future directions. 
PLoS Med 2008;5:e91.
 3 Long CR, Stewart MK, McElfish PA. Health research participants are 
not receiving research results: a collaborative solution is needed. 
Trials 2017;18.
 4 Research participant experience survey report 2018-19. Available: 
https://www. nihr. ac. uk/ documents/ research- participant- experience- 
survey- report- 2018- 19/ 12109 [Accessed 07 Nov 2019].
 5 Health Research Authority. Publishing your research findings, 2019. 
Available: https://www. hra. nhs. uk/ planning- and- improving- research/ 
research- planning/ publishing- your- research- findings/ [Accessed 07 
Nov 2019].
 6  Invo. org. uk.. What is public involvement in research? 2019. Available: 
https://www. invo. org. uk/ find- out- more/ what- is- public- involvement- 
in- research- 2/ [Accessed 07 Nov 2019].
 7 Health Research Authority. Guidance on information at end of study. 
Available:  hra- guidance- end- study- pis- v4- 1_ 20- august- 2015% 20( 6). 
pdf [Accessed 07 Nov 2019].
 8 World Medical Association. World Medical association Declaration 
of Helsinki: ethical principles for medical research involving human 
subjects. JAMA 2013;310:2191–4.
 9 Health Research Authority. Transparency agenda. Available: https://
www. hra. nhs. uk/ about- us/ what- we- do/ our- transparency- agenda/ 
[Accessed 07 Nov 2019].
 10 Schroter S, Price A, Malički M, et al. Frequency and format of clinical 
trial results dissemination to patients: a survey of authors of trials 
indexed in PubMed. BMJ Open 2019;9:e032701.
 11 Staley K, Elliott J. Public involvement could usefully inform ethical 
review, but rarely does: what are the implications? Res Involv 
Engagem 2017;3:30.
 12 Gamble C, Dudley L, Allam A, et al. An evidence base to optimise 
methods for involving patient and public contributors in clinical trials: 
a mixed- methods study. Southampton, UK: NIHR Journals Library, 
2015. https:// europepmc. org/ books/ NBK316049
 13 Ending your project. Available: https://www. hra. nhs. uk/ approvals- 
amendments/ managing- your- approval/ ending- your- project/ 
[Accessed 07 Nov 2019].
 14 Loder E. Pledges for the new year. BMJ;364:k5428.
 15 Denneny C, Bourne S, Kolstoe SE. Registration audit of clinical trials 
given a favourable opinion by UK research ethics committees. BMJ 
Open 2019;9:e026840.
 16 Rhodes RE, de Bruijn G- J. How big is the physical activity intention- 
behaviour gap? A meta- analysis using the action control framework. 
Br J Health Psychol 2013;18:296–309.
 on M












pen: first published as 10.1136/bm
jopen-2019-035730 on 2 F
ebruary 2020. D
ow
nloaded from
 
